Responses

Download PDFPDF

Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Queries on latanaprost
    • , Ophthalmologist
    • Other Contributors:
      • Tariq Ansari
    Dear Editor

    The study is a good comparison of the two medications. I have a few queries for the authors:

    1) Why is latanoprost causing an increase in iris pigmentation; is that not a cause for concern and should this serious side effect not be investigated more fully?

    2) Latanoprost increases uveoscleral outflow; does it bypass the trabecular meshwork or is it causing any blockage in aqueous outflow from th...

    Show More
    Conflict of Interest:
    None declared.